Repetitive Pertussis Toxin Promotes Development of Regulatory T Cells and Prevents Central Nervous System Autoimmune Disease by Weber, Martin S. et al.
Repetitive Pertussis Toxin Promotes Development of
Regulatory T Cells and Prevents Central Nervous System
Autoimmune Disease
Martin S. Weber
1,2*, Mahdia Benkhoucha
3,4, Klaus Lehmann-Horn
1, Deetje Hertzenberg
1, Johann
Sellner
1, Marie-Laure Santiago-Raber
3, Michel Chofflon
3, Bernhard Hemmer
1, Scott S. Zamvil
2.*
Patrice H. Lalive
3,4,5.
1Department of Neurology, Technische Universita ¨tM u ¨nchen, Munich, Germany, 2Department of Neurology, University of California San Francisco, San Francisco,
California, United States of America, 3Department of Neurosciences, Division of Neurology, Geneva University Hospital and University of Geneva, Faculty of Medicine,
Geneva, Switzerland, 4Department of Pathology and Immunology, Geneva University Hospital and University of Geneva, Faculty of Medicine, Geneva, Switzerland,
5Department of Genetics and Laboratory Medicine, Geneva University Hospital, University of Geneva, Faculty of Medicine, Geneva, Switzerland
Abstract
Bacterial and viral infections have long been implicated in pathogenesis and progression of multiple sclerosis (MS).
Incidence and severity of its animal model experimental autoimmune encephalomyelitis (EAE) can be enhanced by
concomitant administration of pertussis toxin (PTx), the major virulence factor of Bordetella pertussis. Its adjuvant effect at
the time of immunization with myelin antigen is attributed to an unspecific activation and facilitated migration of immune
cells across the blood brain barrier into the central nervous system (CNS). In order to evaluate whether recurring exposure to
bacterial antigen may have a differential effect on development of CNS autoimmunity, we repetitively administered PTx
prior to immunization. Mice weekly injected with PTx were largely protected from subsequent EAE induction which was
reflected by a decreased proliferation and pro-inflammatory differentiation of myelin-reactive T cells. Splenocytes isolated
from EAE-resistant mice predominantly produced IL-10 upon re-stimulation with PTx, while non-specific immune responses
were unchanged. Longitudinal analyses revealed that repetitive exposure of mice to PTx gradually elevated serum levels for
TGF-b and IL-10 which was associated with an expansion of peripheral CD4
+CD25
+FoxP3
+ regulatory T cells (Treg). Increased
frequency of Treg persisted upon immunization and thereafter. Collectively, these data suggest a scenario in which
repetitive PTx treatment protects mice from development of CNS autoimmune disease through upregulation of regulatory
cytokines and expansion of CD4
+CD25
+FoxP3
+ Treg. Besides its therapeutic implication, this finding suggests that
encounter of the immune system with microbial products may not only be part of CNS autoimmune disease pathogenesis
but also of its regulation.
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Introduction
Evidence suggests that in the pathogenesis of multiple sclerosis
(MS), viral or bacterial agents may trigger or mislead activation of
an immune system with the general potential to generate a self-
reactive immune response [1,2,3]. Among viral candidates,
association with development or progression of MS has been
reported extensively for human herpes viruses (HHV), such as
HHV-6 [4,5,6,7] or Epstein Barr Virus (EBV, summarized in [8]).
It remains to be determined whether this association is causative
and whether one particular microorganism is specifically involved
in MS pathogenesis. The bacterium Bordetella pertussis causes
whopping cough in humans and produces pertussis toxin (PTx) as
its main virulence factor. Like many common childhood
infections, whopping cough acquired at young age is not
significantly associated with later development of MS [9], whereas
it is well supported that in patients with established MS systemic
infections can trigger T cell activation which is associated with an
elevated risk to develop a clinical relapse [10].
In the animal model of MS, experimental autoimmune
encephalomyelitis (EAE), PTx is used to increase disease incidence
and severity when administered simultaneously with the autoim-
mune challenge. The mechanism by which PTx administration
facilitates EAE development is complex and not entirely
PLoS ONE | www.plosone.org 1 December 2010 | Volume 5 | Issue 12 | e16009understood. Structurally, PTx is composed of five proteins (S1, S2,
S3, S4, and S5) and belongs to the A–B class of exotoxins [11].
The B subunit contains S2–S5 and binds to the surface of many
eukaryotic cells. The A subunit S1, is subsequently released into
the cytoplasm where it interferes with the inhibitory activity of Gi
proteins unleashing intracellular signaling [12]. Pro-inflammatory
activity of PTx is mainly attributed to an increased permeabiliza-
tion of the otherwise cell-restrictive blood-brain barrier leading to
an influx of immune cells into the CNS [13,14]. This assumption
may however not be conclusive as recent data suggest that PTx
increases expression of cerebrovascular adhesion molecules
[15,16], proposing an alternative mechanism by which PTx may
facilitate leukocyte migration into the CNS. PTx further promotes
maturation and functional capacity of antigen presenting cells
(APC) [17], increases production and release of pro-inflammatory
cytokines such as IL-12 [18] and decreases secretion of anti-
inflammatory IL-10 [19]. When used as an adjuvant for EAE
induction, PTx reduces number and function of Treg [20,21],
while promoting development of encephalitogenic Th17
cells[22,23]. Taken together, PTx may utilize multiple mecha-
nisms to promote development of EAE.
Several primarily pro-inflammatory bacterial agents including
PTx appear to also have protective properties when the immune
system encounters them under certain circumstances. In this
regard, pre-exposure of mice to Bordetella pertussis itself protected
from subsequent EAE induction [24]. This effect could be
attributed to the toxin produced, as genetically altered PTx failed
to suppress CNS autoimmune disease [25]. Notwithstanding these
initial observations, they left unclear how PTx facilitates EAE in
one setting but may hinder its induction in another setting. In our
study, we demonstrate that mice continuously exposed to PTx are
indeed protected from active EAE induction which was associated
with a markedly decreased proliferation and pro-inflammatory
differentiation of myelin-reactive T cells. Most importantly, we
report here that PTx treatment prior to disease induction elevated
serum levels for TGF-b and IL-10 and promoted expansion and
suppressive function of Treg providing an explanation on how
repetitive exposure to PTX may prevent development of CNS
autoimmune disease.
Results
Continuous PTx treatment is not immunosuppresive and
does not induce tolerization
First, we investigated whether continuous PTx pre-treatment
may exert an unspecific immunosuppressive effect or may have
tolerized mice for PTx, possibly hindering subsequent EAE
induction using this particular adjuvant. Representative mice in
both the PTx pre-treated, as well as in the control-treated group
were sacrificed before EAE immunization and T cell responses to
myelin antigens, PTx, and another mitogen, phytohaemagglutinin
(PHA) were analysed (Fig. 1a–d). Proliferation of splenocytes in
response to stimulation with PTx was indistinguishable in PTx
pre-treated and control-treated mice (Fig. 1a). Similarly, no
difference in proliferation was observed upon non-specific
stimulation with PHA between PTx pre-treated and control-
Figure 1. C57Bl/6 wild-type (12/group) (a–d) or MOG p35-55 TCR transgenic mice (6/group) (e, f) received weekly i.v. injections with
300 ng PTx in 200 ul of PBS or PBS alone for six months. Splenocytes from two representative mice per group were cultured in the presence
of various concentrations of pertussis toxin (PTx) (a, e), phytohemagglutinin (PHA) (b), MOG p35-55 (c, f) or MBP Ac1-11 (d) (representative for two
separate experiments).
doi:10.1371/journal.pone.0016009.g001
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not impaired its mitogenic potential and had not exerted an
apparent tolerizing or immunosuppressive effect.
We next examined whether continuous PTx treatment may
have generated myelin-specific T cell responses due to its
presumed ability to increase permeabilization of the blood-brain-
barrier. As shown in figure 1c and d, no peripheral proliferative
response to myelin antigen was observed though, either in the
group treated with PTx or in the control-treated group. To further
address the question whether repetitively PTx-facilitated transmi-
gration of myelin-specific T cells may be sufficient to induce CNS
autoimmune disease, MOG p35-55 T cell receptor (TCR)
transgenic mice [26] were injected with PTx weekly over six
months. Like wild-type mice, none of these mice, which are highly
susceptible to EAE, developed clinical signs of paralysis through-
out the time of treatment (Table S1). Further, similar to wild-type
mice, PTx treatment did not alter T cell responses to PTx (Fig. 1e)
or MOG p35-55 (Fig. 1f) in MOG p35-55 TCR transgenic mice
either.
Repetitive PTx pre-treatment prevents development of
clinical and histological EAE
Mice treated weekly with PTx were immunized with MOG
p35-55 and evaluated for clinical signs of EAE. In comparison
with the control-treated group, EAE was ameliorated in mice pre-
treated with PTx (mean clinical score +/2 SEM: 1.1 +/2 0.48 vs.
4.3 +/2 0.44; p=0.0001). Further, onset of clinical symptoms was
significantly delayed in the PTx pre-treated group (15 +/2 1 days)
when compared to the control-treated group (10 +/2 7 days;
p=0.011) (Fig. 2a). Representative sections of the spinal cord and
brain were compared between PTx and control-treated mice. The
number of inflammatory lesions as well as the extent of
inflammatory infiltration was lower in the PTx pre-treated group
than in the control-treated group (mean number of inflammatory
lesions per slide +/2 SEM: 8,7 +/2 1.17 vs. 17 +/2 2.7; p,0.05)
(Fig. 2b). Luxol fast blue staining indicated less or no
demyelination in PTx pre-treated group whereas extensive areas
of myelin loss were observed in the control-treated group (Fig. 2c).
Repetitive PTx pre-treatment inhibits pro-inflammatory
differentiation of myelin-specific T cells and promotes
anti-inflammatory differentiation of PTx responsive cells
We next investigated T cell responses to myelin antigen after EAE
induction comparing PTx- and control-treated mice. T cell
proliferation and cytokine release in response to non-specific
stimulation was similar between the PTx-treated and the control-
treated group (Fig. 3a–d). In contrast, in the PTx-treated group, T
cell proliferation was markedly reduced in response to MOG p35-55,
the antigen used for EAE induction (Fig. 3e).In addition, production
of the Th1 cytokine IFN-c was decreased in the PTx pre-treated
group upon re-stimulation with MOG p35-55 (Fig. 3f), but not with
anti-CD3/CD28 (Fig. 3b)o rP T x( Fig. 3j). Release of TNF, a pro-
inflammatory cytokine mainly secreted by activated APC, was also
analyzed. In contrast to IFN-c, TNF production was not different
between both groups neither upon stimulation with anti-CD3/CD28
(Fig. 3c), MOG 35-55 (Fig. 3g), or PTx (Fig. 3k). As we had
observed that PTx pre-treatment protected mice from subsequent
EAE induction, we investigated whether this pre-treatment had
promoted development of anti-inflammatory cytokines with regula-
tive capacity. Splenocytes from PTx-pre-treated mice released
significant amounts of IL-10 specifically upon stimulation with PTx
(Fig.3l),butnotfollowingstimulationwithantiCD3/CD28(Fig.3d)
or re-stimulation with MOG p35-55 (Fig. 3h).
Repetitive PTx pre-treatment promotes development of
CD4
+CD25
+FoxP3
+ Treg
Based upon this observation, we investigated next whether PTx
treatment may enhance serum levels of anti-inflammatory
cytokines. We thus injected mice weekly with PTx or the non-
self antigen ovalbumin (OVA; 323–339). Serum cytokine levels
were determined every 3 weeks after initiation of treatment. As
shown in figure 4a, weekly injections with PTx elevated serum
levels of IL-10 starting from week 9 after treatment initiation. Even
more prominently, PTx injections raised serum levels of TGF-b
(Fig. 4b) starting as early as 6 weeks after the first injection with
PTx. In contrast, pro-inflammatory cytokines levels such as TNF
(Fig. 4c) or IFN-c (Fig. 4d) were not elevated.
As TGF-b is centrally involved in development and mainte-
nance of Treg [27], we analysed whether PTx pre-treatment was
also associated with an increase in the frequency of
CD4
+CD25
+FoxP3
+ Treg. As shown in figure 4e, repetitive
PTx treatment gradually elevated the frequency of splenic
CD4
+CD25
+FoxP3
+ Treg as well as the mean FoxP3 expression
of CD4
+CD25
+ T cells, starting as early as 3 weeks after initiation
of PTx treatment. In order to investigate whether these
phenomenological changes would translate into an enhanced
regulatory function within the CD4
+ T cell compartment, we
performed co-culture suppression assays. As displayed in
figure 5a, CD4
+ T cells from PTx-, but not from control-treated
mice dose-dependently suppressed proliferation of myelin-specific
T cells. Upon immunization (at week 10), PTx-treated mice -as
expected- developed significantly less severe EAE compared to the
OVA-treated control group (Fig. 5b). At the peak of disease
severity, clinical benefit was associated with a sustained increase of
Treg (Fig. 5c) and significantly elevated serum levels of IL-10
(Fig. 5d).
Discussion
PTx is widely used as an adjuvant to induce EAE. Its co-
administration with myelin antigen enhances incidence and
severity of EAE and even renders otherwise resistant strains
susceptible to EAE [13,28]. This EAE-facilitating effect is not
restricted to PTx, but has also been demonstrated for other
bacterial antigens such as the superantigen staphylococcal
enterotoxin B [29,30,31]. In our study, we first administered
PTx weekly for six months in a dose used for EAE induction into
mice susceptible to MOG-induced EAE. We hypothesized that
through repetitive permeabilization of the blood-brain-barrier
peripherally activated immune cells could infiltrate into the CNS
where they may recognize myelin antigen. However, none of the
mice continuously exposed to PTx developed myelin-specific T
cell responses or showed any sign of paralysis throughout the
course of PTx treatment. We also tested repetitive PTx treatment
in MOG p35-55 TCR transgenic mice which contain a high
frequency of myelin-recognizing T cells. 30% of these mice
develop spontaneous optic neuritis, in a few cases combined with
EAE symptoms [26]. However, while these mice were treated over
a period of 6 months, repetitive PTx injections failed to increase
EAE incidence in this strain as well.
In contrast, mice repetitively pre-treated with PTx were largely
protected from subsequent EAE induction which is in accordance
with earlier studies [24,25]. Interestingly, in experimental
autoimmune uveoretinitis (EAU) a comparable protective effect
was observed with a single large dose of PTx [32], or when
treatment begun after EAU was established [33]. Mice continu-
ously exposed to PTx in our study exhibited markedly decreased
proliferation and pro-inflammatory differentiation of myelin-
Pertussis Toxin Can Expand Treg in EAE
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strongly pro-inflammatory, EAE-facilitating properties protect
from the same disease when given repetitively prior to myelin
antigen immunization? Several possibilities could account for this
intuitively contradictive phenomenon. Most pro-inflammatory
properties of PTx are frequently explained by its impairment of
inhibitory G proteins. PTx was shown to enhance production of
IL-12 and TNF facilitating development of Th1 responses [18].
More recent studies indicate that PTx administered as an adjuvant
also promotes generation of IL-17-producing CD4
+ T cells. In this
regard, it has been demonstrated that PTx is required for efficient
Th-1-, but even more so for Th-17 differentiation of myelin-
specific T cells [23]. Another study could identify an enhanced
release of IL-6 as the key factor for PTx-mediated pro-
inflammatory Th-17 differentiation [22], which also occurred in
models of other inflammatory conditions [34]. Presumably also
through a transient upregulation of IL-6, PTx as an adjuvant to an
immunogenic stimulus suppresses the frequency of
CD4
+CD25
+FoxP3
+ Treg [20,21]. One possible explanation for
the opposing effect of the repetitive application could have been
that continuous activation may have triggered or facilitated T cell
apoptosis [35]. Data indicate that activated T cells are particularly
susceptible to apoptosis [36,37], which could have decreased the
frequency of self-reactive effector T cells before EAE induction.
However, the unimpaired proliferation and pro-inflammatory
differentiation of myelin-reactive T cells in repetitively PTx pre-
Figure 2. C57Bl/6 mice received weekly i.v. injections with 300 ng PTx in 200 ul of PBS or PBS alone. After six months of PTx injection,
mice were immunized with MOG p35-55 in CFA and injected i.v. with 300 ng PTx in PBS immediately following the immunization and 48 h later. (a)
Mice were followed for clinical signs of EAE (10 mice/group, mean severity is indicated as group average +/2 SEM, * indicates p,0.05). (b+c) 50 days
after EAE induction, CNS tissue from all mice was analysed for histological signs of EAE. Spinal cords were isolated and representative cervical, lumbal
and thoracical sections were evaluated for inflammatory lesions. (b) Indicated is the average number of lesions per slide +/2 SEM in each group
(* indicates p,0.05). (c) Shown are representative slides stained with H&E (upper panels) or LFB (lower panels, magnification X100), (representative
for two separate experiments).
doi:10.1371/journal.pone.0016009.g002
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enhanced apoptosis of effector T cells is unlikely to account for
the observed EAE resistance. Alternatively, continuous exposure
to PTx could have induced T cell anergy [38], thereby specifically
abolishing PTx’s T cell activating property at the time of
immunization. This assumption is fuelled by the fact that pre-
treatment with Mycobacterium tuberculosis, which is also part of
many active EAE induction protocols, similarly conferred
protection against CNS autoimmune disease, whereas pretreat-
ment with other bacterial components, e.g. from Escheriachia coli,
Shigella or Staphylococcus aureus failed to do so [24]. However, at
least in the case of Mycobacterium tuberculosis, it has been
demonstrated that the protective effect could be attributed to a 12-
kDa protein which failed to activate encephalitogenic T
lymphocytes [39], suggesting that the domain conferring protec-
tion and the one facilitating EAE are not identical. The possibility
of T cell anergy as the explanation for EAE resistance conferred by
chronic PTx treatment appears further unlikely in the light of the
unaltered immune cell response to PTx in both wild-type and
MOG p35-55 TCR transgenic mice treated with PTx over several
weeks.
In our study, PTx-mediated protection from CNS autoimmune
disease was associated with an enhanced frequency and function of
CD4
+CD25
+FoxP3
+ Treg. Development of Treg was associated
with elevated serum levels for TGF-b and IL-10, two cytokines
centrally involved in development and maintenance of Treg
[27,40]. These regulatory cytokines are produced by a variety of
immune cells, including T cells as well as various APC [41].
Although it remains to be determined which cell(s) released IL-10
and TGF-b in response to repetitive PTx exposure, our current
study may provide a hint: Splenocytes isolated from PTx-treated
mice secreted enhanced amounts of IL-10 specifically upon re-
exposure to PTx, but not upon antigen non-specific T cell
activation. These findings could suggest that IL-10 and TGF-b
was rather than by T cells produced by APC, which may potently
promote expansion of CD4
+CD25
+FoxP3
+ Treg while presenting
Ag to naı ¨ve T cells [42,43].
In MS [44], as well as in other autoimmune conditions [45],
frequency and function of Treg have been found to be impaired.
Therapeutic restoration of Treg frequency to the levels of healthy
control subject is associated with treatment benefit in MS [46].
Extensive investigations in mice have demonstrated that FoxP3
+Treg
control development and severity of experimental CNS autoimmune
disease (for review [47]): Adoptively transferred Treg significantly
protected recipient mice from clinical EAE [48]; conversely,
depletion of Treg has been shown to substantially increase EAE
susceptibility as well as severity of its disease course [49,50]. In our
study, we have demonstrated that repetitive PTx treatment elevated
frequency as well as mean FoxP3 expression of CD4
+CD25
+FoxP3
+
T cells. PTx-expanded Treg efficiently suppressed proliferation of
myelin-specific T cells. Taken together and in context with existing
literature, these findings support the assumption that repetitive PTx
administration may have protected mice from subsequent EAE
induction trough prior expansion of Treg.
Figure 3. C57Bl/6 mice received weekly i.v. injections with 300 ng PTx in 200 ml of PBS or PBS alone. After six months, mice were
immunized with MOG p35-55 in CFA and injected i.v. with 300 ng PTx in PBS immediately following the immunization and 48 h later. 50 days after
EAE induction, isolated splenocytes from 4 (control-treated group) and 6 (PTx-treated group) representative mice were cultured with anti-CD3
(0,5 mg/ml) and anti-CD28 (1 mg/ml) (a–d), MOG p35-55 (e–h) or PTx (i–l) and evaluated for proliferation (a, e, i), secretion of IFN-c (b, f, j), TNF (c, g,
k) and IL-10 (d, h, l) (* indicates p,0.05, ** p,0.001, *** p,0.0001; representative for two separate experiments).
doi:10.1371/journal.pone.0016009.g003
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antigen PTx gradually increased secretion of regulatory cytokines and
expanded the population of Treg. This immunological alteration was
associated with protection from CNS autoimmune disease. Besides its
therapeutic implication, this finding indicates that in general,
microbial products may not only be involved in the pathogenesis of
CNS autoimmune disease but also in its regulation.
Materials and Methods
Ethics statement
All experiments carried out in this study were strictly performed
in a manner to minimize suffering of laboratory mice. The
individual protocols were approved by the respective committees
at the University of California, San Francisco, USA (protocol
approval number AN083156-01C), the Technische Universita ¨t
Mu ¨nchen, Munich, Germany (protocol approval number 55.2-1-
54-2531-67-09) and the University of Geneva (protocol ID
number: 31.1.1005/3167/3).
Mice and EAE induction. C57BL/6 female mice, 5–8 weeks
of age, were purchased from the Jackson Laboratory (Bar Harbor,
MN). C57BL/6 MOG p35-55-specific TCR transgenic (2D2)
mice [26] were kindly provided by Vijay K. Kuchroo (Harvard
University) and Thomas Korn (Technische Universita ¨tMu ¨nchen).
Mouse myelin oligodendrocyte glycoprotein (MOG) peptide 35-55
(MEVGWYRSPFSRVVHLYRNGK) was synthesized and
purified (.99%) by Auspep (Parkville, Australia). Age-matched
mice were immunized subcutaneously (s.c.) with 25 mg MOG p35-
55 in 0.1 ml of PBS emulsified in an equal volume of complete
Freund’s adjuvant (CFA) supplemented with 2 mg/ml of
mycobacterium tuberculosis H37RA on day 0 (DIFCO
Laboratories, Detroit, Michigan, USA). After immunization and
48 hrs later, mice received an intravenous (i.v.) injection of 300 ng
of PTx in 0.2 ml of PBS [42,51]. Individual animals were observed
daily and clinical scores were assessed in a blinded fashion as
follows: 0= no clinical disease, 1= loss of tail tone only, 2= mild
monoparesis or paraparesis, 3= severe paraparesis, 4= para-
plegia and/or quadraparesis, and 5= moribund or death.
Figure 4. C57Bl/6 mice received weekly i.v. injections with 300 ng PTx or OVA 323–339 (control) in PBS. Serum cytokine IL-10 (a), TGF-b
(b), TNF (c) and INF-c (d) were determined at week 0-3-6-9 post PTx treatment. CD4
+CD25
+FoxP3
+ Treg were analysed by flow cytometry at week 0-3-
6-9 post PTx treatment (e; upper panels: indicated is the percentage of CD4
+CD25
+ within all CD4
+ T cells; middle panels: FoxP3 expression of
CD4
+CD25
+ cells; lower panels: mean FoxP3-FITC fluorescence intensity of CD4
+CD25
+ cells, * indicates p,0.05) (3 mice/group/time point;
representative for three separate experiments).
doi:10.1371/journal.pone.0016009.g004
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Biological Laboratories Inc. (Campbell, USA). Age-matched mice
received weekly i.v. injections with 300 ng PTx or OVA 323-339
(Abgent, Inc., San Diego, USA) in 0.2 ml of PBS or PBS alone.
Proliferation Assays. Primary proliferative responses were
measured using splenocytes. 5610
5 spleen cells were cultured with
antigen in 0.2 ml RPMI medium supplemented with 5610
25 M2 -
mercaptoethanol, 2 mM glutamine, 100 mg/ml penicillin, and
100 mg/ml streptomycin. Anti-mouse CD3/CD28 or PHA (BD
Biosciences, FranklinLakes,USA) were used as positive control. For
co-culture assays, 2610
4 MACS (CD11c)-separated dendritic cells
were used as APC together with 4610
4 MACS (CD4)-separated
MOG p35-55-specific T cells from TCR transgenic (2D2) mice. In
order to evaluate the suppressive capacity of Treg, increasing
numbers of MACS (CD4)-separated T cells from PTx- or
ova(control)-treated mice were added to the culture. After 72 hr,
all proliferation assays were pulsed with 1 mCi [
3H]-thymidine and
harvested 16 hr later. Mean counts per minute (cpm) of [
3H]-
thymidine incorporation was calculated for triplicate cultures.
Cytokine analysis. Serum samples were obtained at the
time-point indicated for cytokine analysis. Culture supernatants
were collected at two time-points, 72-hr (TNF, IFN-c, TGF-b),
and 120-hr (IL-10). ELISA assays were performed using paired
monoclonal antibodies specific for corresponding cytokines per
manufacturer’s recommendations (Pharmingen, San Diego, CA).
The results for ELISA assays are expressed as an average of
triplicate wells +/2 SD. SOFTmax ELISA plate reader and
software was used for data analysis (Molecular Devices
Corporation, Sunnyvale, CA).
FACS analysis of CD4
+CD25
+ FoxP3
+ Treg. Development
of CD4
+CD25
+FoxP3
+ Treg was evaluated using a FACS staining
kit by eBiosience (San Diego, USA).
Histopathology. Brains and spinal cords of mice were fixed
in 10% formalin. Sections were stained with Luxol fast blue-
hematoxylin and eosin. Parenchymal inflammatory lesions were
counted as described [52,53].
Statistical analysis. Data are presented as mean 6 SEM.
For clinical scores significance between groups was examined
Figure 5. C57Bl/6 mice received weekly i.v. injections with 300 ng PTx or OVA 323–339 (control) in PBS. After 4 weeks, splenic CD4
+ T
cells were purified (3 mice/group) and co-cultured with 2610
4 dendritic cells and 4610
4 MOG p35-55 specific T cells from TCR transgenic (2D2) mice
in the presence of 20 mg/ml MOG p35-55. Proliferation at the indicated ratio of MOG p35-55 specific CD4
+ T cells (2D2)/CD4
+ T cells from PTx-/ova-
treated mice (PTx/ova) (1/1, 1/5, 1/10) is shown as percentage of the proliferative response without CD4
+ T cells from PTx-/ova-treated mice (ratio 1/0)
(a). After 10 weeks, EAE was induced with MOG p35-55 (8 mice/group). PTx pre-treatment significantly ameliorated disease severity (b). At the peak of
clinical EAE severity, the frequency of CD4
+CD25
+FoxP3
+ Treg and serum level of IL-10 was evaluated. Clinical benefit of PTx-pretreated mice was
associated with expansion of FoxP3
+ Treg cells (c; left panels: indicated is the percentage of CD4
+CD25
+ within all CD4
+ T cells; right upper panel:
FoxP3 expression of CD4
+CD25
+ cells; right lower panel: mean FoxP3-FITC fluorescence intensity of CD4
+CD25
+ cells) and elevated serum levels for IL-
10 (d) (*indicates p,0.05, ** indicates p,0.001; representative for two separate experiments).
doi:10.1371/journal.pone.0016009.g005
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significant. All other statistical analysis was performed using a one-
way multiple-range analysis of variance test (ANOVA) for multiple
comparisons; individual p values are indicated.
Supporting Information
Table S1 C57Bl/6 wild-type (WT) or MOG p35-55 T cell
receptor (TCR) transgenic (Tg) mice received weekly i.v. injections
with 300 ng PTx in 200 ul of PBS or PBS alone for six months.
Mice were evaluated weekly for clinical signs of EAE.
(TIF)
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